Zura Bio (NASDAQ:ZURA) Stock Price Down 5.3% – What’s Next?

Zura Bio Limited (NASDAQ:ZURA)’s stock price was down 5.3% on Monday . The stock traded as low as $5.50 and last traded at $5.5040. Approximately 368,677 shares traded hands during mid-day trading, a decline of 44% from the average daily volume of 656,613 shares. The stock had previously closed at $5.81.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. Oppenheimer lowered their price target on shares of Zura Bio from $16.00 to $15.00 and set an “outperform” rating for the company in a report on Friday, March 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zura Bio in a research report on Wednesday, April 8th. Chardan Capital boosted their target price on shares of Zura Bio from $10.00 to $11.00 and gave the stock a “buy” rating in a research note on Monday, March 23rd. Finally, Wedbush assumed coverage on Zura Bio in a report on Monday, February 9th. They issued an “outperform” rating and a $15.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Zura Bio currently has a consensus rating of “Moderate Buy” and a consensus target price of $10.75.

Zura Bio Stock Down 1.5%

The firm has a market capitalization of $501.92 million, a price-to-earnings ratio of -4.99 and a beta of 0.24. The company has a fifty day moving average price of $6.15 and a two-hundred day moving average price of $5.07.

Zura Bio (NASDAQ:ZURA) last announced its earnings results on Thursday, March 19th. The company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.31). On average, equities analysts anticipate that Zura Bio Limited will post -0.63 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, major shareholder Ai Biotechnology Llc acquired 2,000,000 shares of the stock in a transaction that occurred on Thursday, February 26th. The shares were purchased at an average cost of $6.25 per share, for a total transaction of $12,500,000.00. Following the transaction, the insider directly owned 6,552,725 shares in the company, valued at approximately $40,954,531.25. This represents a 43.93% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. 22.10% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Zura Bio

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Allworth Financial LP acquired a new position in shares of Zura Bio during the 4th quarter worth $30,000. Scientech Research LLC purchased a new stake in Zura Bio during the third quarter worth $45,000. AQR Capital Management LLC acquired a new stake in Zura Bio in the first quarter valued at $72,000. Forefront Wealth Partners LLC acquired a new position in shares of Zura Bio during the 3rd quarter worth $93,000. Finally, Bank of America Corp DE grew its stake in Zura Bio by 31.9% in the 4th quarter. Bank of America Corp DE now owns 41,222 shares of the company’s stock valued at $103,000 after acquiring an additional 9,966 shares during the last quarter. Institutional investors and hedge funds own 61.14% of the company’s stock.

Zura Bio Company Profile

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.